ReviewInternational journal of molecular sciences2022
Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Therapeutic siRNA: Mechanisms, challenges, strategies, and clinical translation.Chinese medical journal · 2026Review
- Article
- Addressing adherence challenges in long-term statin treatment among Asian populations: Current gaps and proposed solutions.American journal of preventive cardiology · 2025Review
- Pan-cancer analysis reveals the potential role of DHCR24 in bladder cancer via interactions with HRAS to facilitate cholesterol synthesis.Oncology letters · 2025Article
- The Effect of Statin Therapy on Hemorheological Parameters of Patients with Clinically Silent Ischemic Foci of the Brain.International journal of molecular sciences · 2025Article
- Neovascularization in Atherosclerotic Plaques: Clinical Implications, Detection, and Prevention Strategies.Reviews in cardiovascular medicine · 2025Review
- Therapeutic potential of3 Biotech · 2025Article
- Exploring the Cardiovascular Protective Effects of Baicalin: A Pathway to New Therapeutic Insights.Current topics in medicinal chemistry · 2025Review
- Review
- Silicon as a Functional Meat Ingredient Improves Jejunal and Hepatic Cholesterol Homeostasis in a Late-Stage Type 2 Diabetes Mellitus Rat Model.Foods (Basel, Switzerland) · 2024Article
- The Polypill: A New Alternative in the Prevention and Treatment of Cardiovascular Disease.Journal of clinical medicine · 2024Review
- Statins-Their Role in Bone Tissue Metabolism and Local Applications with Different Carriers.International journal of molecular sciences · 2024Review
- Role of G-Protein-Coupled Receptors in Cardiovascular Diseases.International journal of molecular sciences · 2023Article
- The Link between Magnesium Supplements and Statin Medication in Dyslipidemic Patients.Current issues in molecular biology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerotic cardiovascular disease (ASCVD) morbidity and mortality are decreasing in high-income countries, but ASCVD remains the leading cause of morbidity and mortality in high-income countries. Over the past few decades, major risk factors for ASCVD, including LDL cholesterol (LDL-C), have been identified. Statins are the drug of choice for patients at increased risk of ASCVD and remain one of the most commonly used and effective drugs for reducing LDL cholesterol and the risk of mortality and coronary artery disease in high-risk groups. Unfortunately, doctors tend to under-prescribe or under-dose these drugs, mostly out of fear of side effects. The latest guidelines emphasize that treatment intensity should increase with increasing cardiovascular risk and that the decision to initiate intervention remains a matter of individual consideration and shared decision-making. The purpose of this review was to analyze the indications for initiation or continuation of statin therapy in different categories of patient with high cardiovascular risk, considering their complexity and comorbidities in order to personalize treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.